Hangzhou TianMuShan Pharmaceutical Enterprise Co 600671.SS · CNY
Health Care · Shanghai · 🇨🇳 China
17.32
-3.29%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hangzhou TianMuShan Pharmaceutical Enterprise Co
Its shares trade on Shanghai under the ticker 600671.SS. It has been listed since 23 August 1993. In the fiscal year to 31 December 2025, it reported revenue of CN¥211.8m and net income of CN¥17.6m. At that date it held total assets of CN¥442.0m and shareholders' equity of CN¥70.0m.
Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd. engages in the sale of medicines and health products. The company is headquartered in Hangzhou, Zhejiang. The firm is mainly engaged in the manufacture of chemical drug substances, processing of Chinese herbal pieces as well as the manufacture of traditional Chinese medicine preparation and Western medicine. The firm's main products are bright eye drops, FufangXianzhuliYe, amoxicillin and clavulanate potassium tablets, Hechedazao Jiaonang, Liu Wei Di Huang oral liquid, menthol, and peppermint oil. The firm mainly operates its business in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Aug 1993
- Employees
- 371
- Website
- hztmyy.com ↗
Leadership
Pay as last reported
- Mr. Jiayong LiuChairman of the Board, since 2023
- Mr. Hongjian YuChief Financial Officer, Deputy General Manager (Vice President), Director, since 2023
- Ms. Yinjun LiDeputy General Manager (Vice President)
- Mr. Xuejian SunGeneral Manager
- Mr. Shengbin JiDeputy General Manager
- Mr. Guojun DangSecretary of the Board, Director, since 2021
- Mr. Junde HuangDirector
- Ms. Yunsong JiaDirector
- Mr. Shibin LiuDirector
- Hong CuiIndependent Director
- Mr. Xuemin NieIndependent Director
- Mr. Yang PeiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bright eye drops and FufangXianzhuliYe are top-selling products in the domestic market.
- The company manufactures traditional Chinese medicine and Western medicine in Hangzhou.
- 371 employees support the production of chemical drug substances and herbal pieces.
Weaknesses
- Limited domestic market focus restricts international expansion opportunities.
- No mention of international operations or global market presence.
- Dependence on domestic market may limit growth potential.
Opportunities
- Expanding into international markets for traditional Chinese medicine products.
- Growing demand for herbal products in the domestic health care sector.
- Potential for new product development in pharmaceuticals and health care.
Threats
- Competition from other domestic pharmaceutical companies in China.
- Regulatory changes in the Chinese health care industry could impact operations.
- Economic downturns may reduce consumer spending on health products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.